Download biomedica product list
Biomarkers of improved health after quitting smoking
Cigarette smoking is involved in the development of cardiovascular disease (CVD). It leads to changes in a number of biomarkers reflecting inflammation, oxidative stress, endothelial function, and lipid levels (1, 2) . A recent study investigated changes in biomarkers in individuals who stopped smoking (1). One of the biomarkers to measure oxidative stress in serum of individuals who quit smoking was “anti-oxidized low-density lipoprotein (anti-oxLDL) antibodies”. The anti-oxLDL antibodies were quantified with an assay from Biomedica.
Biomarkers of improved health after quitting smoking
Anti-Oxidized LDL Autoantibodies
Oxidized low-densitity lipoprotein (oxLDL) is believed to play a crucial role in in the development and progression of coronary artery disease (CAD) that involves atherosclerosis and inflammation. oxLDL in macrophages and smooth muscle cells accumulates and causes foam cell formation, which represents an early stage in the development of the disease. In fact, oxidized LDL appears to be around 24% higher in smokers compared to non-smokers (3). Autoantibodies targeting oxidatively modified LDL particles can serve as a parameter that consistently reflects the ongoing oxidation processes taking place in vivo. Studies demonstrate increased levels of autoantibodies against oxLDL in the bloodstream of individuals with coronary artery disease (4)
How can “Anti-Oxidized LDL Autoantibodies” be measured?
Autoantibodies targeting oxidatively modified LDL particles can easily be measured with a conventional ELISA assay.
Anti-Oxidized LDL Autoantibody ELISA (oLAB) assay (cat. no. BI-20032)
Highlights
Literature
- Changes in biomarkers of endothelial function, oxidative stress, inflammation and lipids after smoking cessation: A cohort study. Colsoul ML et al., Eur J Clin Invest. 2023 Aug;53(8):e13996. doi: 10.1111/eci.13996. Epub 2023 Apr 8. PMID: 37000021.
- Suitability of biomarkers of biological effects (BOBEs) for assessing the likelihood of reducing the tobacco related disease risk by new and innovative tobacco products: A literature review. Scherer G Regul Toxicol Pharmacol. 2018 Apr;94:203-233. doi: 10.1016/j.yrtph.2018.02.002. Epub 2018 Feb 9. PMID: 29428304.
- Circulating oxidized low density lipoprotein, autoantibodies against them and homocysteine serum levels in diagnosis and estimation of severity of coronary artery disease. Faviou E et al., Free Radic Res. 2005 Apr;39(4):419-29. doi: 10.1080/10715760500072156. PMID: 16028367.
- Biomarkers of improved health outcomes after smoking cessation. Neal L. Benowitz et al., Addiction Neuroscience,5: 2023, 100054,ISSN 2772-392. ISSN 2772-3925.